Back to top
more

Shockwave Medical Inc. (SWAV)

(Delayed Data from NSDQ)

$43.43 USD

43.43
437,633

+2.29 (5.57%)

Updated May 3, 2019 04:00 PM ET

After-Market: $43.32 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Myriad Genetics' (MYGN) UroSuite to Improve Tailored Treatment

by Zacks Equity Research

Myriad Genetics' (MYGN) latest launch is expected to aid clinicians with access to tools that can assist them with turnaround times and report interpretation.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Here's Why You Should Retain Intuitive Surgical (ISRG) Stock

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Improving margins buoy optimism.

Patterson Companies (PDCO) Inks Deal to Expand Product Suite

by Zacks Equity Research

Patterson Companies' (PDCO) latest buyout is expected to significantly expand its value-add platform.

Should iShares Morningstar SmallCap ETF (ISCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCB

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Is First Trust Mid Cap Growth AlphaDEX ETF (FNY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FNY

Shockwave Medical (SWAV) Beats on Q3 Earnings & Revenues

by Zacks Equity Research

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.

Should iShares Morningstar SmallCap Growth ETF (ISCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCG

Shockwave Medical (SWAV) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Shockwave Medical (SWAV) delivered earnings and revenue surprises of 35.29% and 4.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RFG

What's in Store for Shockwave Medical (SWAV) in Q3 Earnings?

by Zacks Equity Research

Shockwave Medical's (SWAV) third-quarter results are likely to reflect solid performance of its IVL system across geographies.

    Ekso Bionics (EKSO) Reports Q3 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Ekso Bionics (EKSO) delivered earnings and revenue surprises of -37.50% and 7.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

    Shockwave Medical (SWAV) Stock Moves -0.38%: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Shockwave Medical (SWAV) closed at $292.05, marking a -0.38% move from the previous day.

    Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for IWO

    Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for VTWG

    Shockwave Medical (SWAV) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    Shockwave Medical (SWAV) closed the most recent trading day at $296.82, moving +0.51% from the previous trading session.

    Shockwave Medical (SWAV) Stock Jumps 6%: Will It Continue to Soar?

    by Zacks Equity Research

    Shockwave Medical (SWAV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for FNY

    Abiomed's (ABMD) Latest Impella Offering Approved by the FDA

    by Zacks Equity Research

    Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.

    Veeva Systems' (VEEV) New Launch to Streamline Clinical Data

    by Zacks Equity Research

    Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.

    Shockwave Medical (SWAV) Dips More Than Broader Markets: What You Should Know

    by Zacks Equity Research

    In the latest trading session, Shockwave Medical (SWAV) closed at $269.61, marking a -1.44% move from the previous day.

    Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover

    by Zacks Equity Research

    Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.

    Veeva Systems' (VEEV) New Launch to Enhance Digital Trials

    by Zacks Equity Research

    Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.

    BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence

    by Zacks Equity Research

    BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.